Evaluación del screening en el diagnóstico actual del cáncer de próstatadesarrollo de nuevos biomarcadores urinarios

  1. Jiménez Pacheco, Antonio
  2. Peinado Herreros, José María
  3. López Luque, Alfonso
  4. Iríbar Ibabe, María Concepción
Revista:
Actualidad médica

ISSN: 0365-7965

Año de publicación: 2011

Tomo: 96

Número: 784

Páginas: 26-35

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openDIGIBUG editor

Otras publicaciones en: Actualidad médica

Resumen

El cáncer de próstata (CaP) es el tumor maligno no cutáneo más frecuente en el hombre, y supone la segunda causa de muerte por cancer en hombres en EEUU, sólo superado por el cáncer de pulmón. Constituye unos de los problemas sanitarios más importantes en nuestro medio, tanto en términos de morbimortalidad, como de impacto social, económico o sobre la calidad de vida. Sin embargo a pesar de tratarse de un cáncer muy prevalente el screening del cáncer de próstata es aún controvertido. Las principales técnicas utilizadas en la evaluación inicial del cáncer de próstata son el examen digito-rectal, antígeno prostático específico (PSA) sérico, y la ecografía transrectal de próstata. El PSA, es considerado actualmente, el biomarcador más importante para la detección y monitorización del CaP, sin embargo carece de especificidad. Esto ha llevado a la búsqueda de biomarcadores tanto urinarios como en sangre, que supongan una alternativa, para superar esa falta de especificidad. Recientemente se han propuesto una serie de marcadores biológicos alternativos en distintos tipos de tumores, entre los que se encuentra el CaP.

Referencias bibliográficas

  • Andriole GF. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360:1310-9.
  • Andriole GL, Catalona WJ. Using PSA to screening for prostate cancer; The Washington University experience. Urol Clin North Am1993; 20: 647-51.
  • Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y, Tremblay RR. Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J 2007; 1: 377–81.
  • Bonis J. Cribado de cáncer poblacional. AMF 2010; 6:480-6.
  • Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostatespecific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59, 5975–5979.
  • Cabanes A, Perez-Gomez B, Aragones N, Pollan M, Lopez-Abente G. La situación del cáncer en España, 1975-2006. Instituto de Salud Carlos III. Madrid, 2009.
  • Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res 2001; 7: 2727–30.
  • Carroll P. Serum prostate specific antigen for prostate cancer early detection: total, free, age stratified, or complexed? Urology 2001; 57; 591-3.
  • Carter HB, Epstein JI. Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate.World J Urol 1997; 15: 359.
  • Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279:1542-47.
  • CatalonaWJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
  • Chiou CC, Chang PY, Chan EC, Wu TL, Tsao KC, Wu JT. Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers. Clin Chim Acta 2003; 334: 87–94.
  • Chu MT. Prostate-specific antigen and early detection of prostate cancer. Tumor Biol 1997; 18: 123- 34.
  • Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O. Olfactory Detection of Prostate Cancer by Dogs Sniffing Urine: A Step Forward in Early Diagnosis. Eur Urol 2011; 15: 197-201.
  • Day JR, Jost M, Reynolds A, Groskopf J, Rittenhouse H. PCA3: from basic molecular science to the clinical lab. Cancer letters 2011; 301: 1-6.
  • Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822–6.
  • Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24: 275-82.
  • Fernandez-Serra A, Rubio-Briones J, Garcia-Casado Z, Solsona E, Lopez-Guerrero JA. Cáncer de próstata: la revolución de los genes de fusión. Actas Urol Esp 2011; 35: 420-8.
  • Goessl C, Krause H, Müller M, Heicappell R, Schrader M, Sachsinger J, et al. Fluorescent methylationspecifi polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60: 5941–5.
  • Goessl C, Müller M, Heicappell R, Krause H, Straub B, Schrader M, et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 2001; 58: 335–8.
  • Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res 2003; 9: 2673–7.
  • Granado de la Orden S, Saa Requejo C, Quintas Viqueira A. Situación epidemiológica del cáncer de próstata en España. Actas Urol Esp 2006; 30: 574-82.
  • Graves HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985; 312: 338–43.
  • Hara M, Koyanagi Y, Inoue T, Fukuyama T. Some physico-chemical characteristics of “seminoprotein”, an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII. Nihon Hoigaku Zasshi 1971; 25: 322-4.
  • Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008; 53: 68-80.
  • Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev VB, Mason MD, et al. Guidelines on prostate cancer. EAU 2010: 1-164.
  • Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 2007; 13: 5103–8.
  • Hodge KK, McNeal JE, Terris MK, Stamey TA. Ramdom systematic versus directed ultrasound guided transrectal core biopsies of the prostate J Urol 1989; 142: 71-4.
  • Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W. Quantitative methylation specifi polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005; 23: 6569–75.
  • Hutchinson LM, Chang EL, Becker CM, Ushiyama N, Behonick D, Shih MC, et al. Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem2005; 38: 558–71.
  • Iwakiri J, Granbois K, Wehner N, Graves HC, Stamey T. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. J Urol 1993; 149: 783–6.
  • Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–49.
  • Jiang Z, Woda BA. Diagnostic utility of alphamethylacyl CoA racemase (P504S) on prostate needle biopsy. Adv Anat Pathol 2004; 11: 316–21.
  • Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008; 68: 645–9.
  • Lopez Luque A, Gomez Bermudo J, Marquez Lopez J, Leva Vallejo M, Regueiro Lopez JC, Requena Tapia MJ. Determination of free prostatic specific antigen cut point for the selection of patients in first prostate biopsy. Actas Urol Esp. 2006; 30:13-7.
  • Lu Q, Zhang J, Allison R, Gay H, Yang WX, Bhowmick NA, et al. Identification of extracellular delta catenin accumulation for prostate cancer detection. Prostate 2009; 69: 411–8.
  • Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, et al. Measurement of the proportion of free to total PSA improves diagnostic performance of PSA in the diagnostic gray zone of total PSA. Urology 1995; 46:187-94.
  • Madoz-Gúrpide J, López-Serra P, MartínezTorrecuadrada JL, Sánchez L, Lombardía L, Casal JI. Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol Cell Proteomics 2006; 5: 1471–83.
  • Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J of Cancer 2010; 1: 150-77.
  • Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425men. Cancer 1991; 67: 2949-58.
  • Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med 2009; 7: 4.
  • Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804–9.
  • NelsonWG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-81.
  • Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603–7.
  • Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU International 2009; 105: 166-9.
  • Oh WK, Hurwitz M, D'Amico AV, Richie JP, Kantoff PW. Neoplasms of the Prostate. In: Kufe DW, et al editors. Cancer Medicine. 6th ed. Hamilton, Ontario, Canada: BCDecker Inc; 2003.
  • Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alphamethylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J. Urol 2009; 181: 2508–13.
  • Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, et al. Molecular forms of prostatespecific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology 1997; 50: 715–21.
  • Ploussard G, de la Taille A. Urinarie biomarkers in prostate cancer. Nat Rev Urol 2010; 7: 101- 9.
  • Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen. A decade of discovery-what we have learned and where we are going?. J Urol 1999; 162: 293-306.
  • Proceso hipertrofia benigna de próstata y/o cáncer de próstata. Cartera de Servicios por Procesos Asistenciales Integrados Servicio Andaluz de Salud. http://www.sas.juntaandalucia.es/contenidos/publicaciones/datos/180/html/CSProcAsist2004/ProcesoHipertrofiaProstata.pdf.
  • Rehman I, Azzouzi AR, Catto JW, Allen S, Cross SS, Feeley K, et al. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology 2004; 64. 1238–43.
  • Roehl KA, Antenor LV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2001; 167: 2435-9.
  • Rogers CG, Yan G, Zha S, Gonzalgo ML, Isaacs WB, Luo J, et al. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J Urol 2004; 172: 1501-3.
  • Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, et al. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin. Cancer Res. 2008; 14: 6610–7.
  • Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin. Cancer Res 2009; 15: 4292–8.
  • Sanderson H, Goodman SN, Partin AA, Walsh PC, Epstein JI, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl Cancer Inst 2003 95, 1634–7.
  • Sanz Perez GG, Zudaire Bergara JJ, Maalik A, Lopez Ferrandis J, Sanchez Zalabardo D, Arocena GarciaTapia J, et al. Factores influyentes en la presencia de carcinoma en las biopsias de próstata. Actas Urol Esp 2000; 24: 801-4.
  • Sawyers CL. The cancer biomarker problem. Nature 2008; 452: 548-52.
  • Scardino et al: Early detection of prostate cancer. Hum Pathol 1992; 23: 211-22.
  • Schostak M, Schwall GP, Poznanovi S, Groebe K, Müller M, Messinger D, et al. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol 2009; 181: 343–53.
  • Schröder FH. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360:1320-8.
  • Sokoll LJ, Partin AW, Mikolajczyk SD, Rittenhose HR, Evans CE, Linton HJ, et al. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.Urology 2003; 61: 274-6.
  • Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay JW, Coffey DS. Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res. 1996; 56: 218–22.
  • Taichman RS, Loberg RD, Mehra R, Pienta KJ. The evolving biology and treatment of prostate cancer. J Clin Invest 2007; 117: 2351-61.
  • Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–64.
  • Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008; 10: 1285–94.
  • Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
  • Woodson K, O'Reilly KJ, Hanson JC, Nelson D, Walk EL, Tangrea JA. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol 2008; 179: 508–11.
  • You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, et al. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 2010; 73: 10-22.
Fuente de los datos: Dialnet